GlassScriptPhysician profile
Patricia Serna
NPI 1124358791
$2,822.94
in general payments reported to CMS, 2019-2025
16 companies · $663 in 2025
The $663 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,007 · 2022: $685 · 2023: $283 · 2024: $185 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097 · Education: $33.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.16 |
| Education | $33.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $767.64 | 2021-2025 | Myrisk |
| Janssen Biotech, INC. | $363.54 | 2021-2022 | |
| Lilly USA, LLC | $347.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $249.51 | 2021-2022 | |
| Seagen INC. | $159.37 | 2021-2022 | |
| Glaxosmithkline, LLC. | $130.93 | 2021 | |
| G1 Therapeutics, INC. | $121.82 | 2023 | Cosela |
| Beigene USA, INC. | $119.82 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $107.21 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.60 | 2025 | |
| Daiichi Sankyo INC. | $100.39 | 2025 | Enhertu |
| Kite Pharma, INC. | $88.68 | 2021 | |
| Tempus Ai, INC | $74.83 | 2024 | |
| Celgene Corporation | $43.34 | 2024-2025 | Opdivo |
| Abbvie INC. | $23.43 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Serna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.